Q3 2025 Earnings Call Transcript November 13, 2025 Vaxart, Inc. beats earnings expectations. Reported EPS is $-0.04, expectations were $-0.07. Operator: Greetings, and welcome to the Vaxart Business ...
FOR some people, it starts with a scratchy throat followed by a tickly cough. For others, a headache comes first, before a ...
With this year’s ‘quad-demic’ of flu, Covid, RSV and norovirus starting to surge, here are the symptoms to watch for and how ...
Received FDA IND clearance to evaluate CDI-988 as both norovirus preventive and treatmentExpects to initiate CDI-988 Phase 1b ...
Entered into an exclusive license agreement with Dynavax for the Company's COVID-19 oral pill vaccine candidate for potential cumulative proceeds of up to $700 million plus royalties Completed enrollm ...
Norovirus triggers symptoms such as vomiting and diarrhoea. While it can be extremely unpleasant, it typically resolves ...
Louisville Metro Health and Wellness report public health researchers have detected an increase in norovirus levels in ...
Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected ...
The median concentration across all sites in October 2025 was 17.1k copies/gram (cp/g), a decrease of ~74% compared to ...
We review the current state of influenza, from its virology and public health impact to the limitations of vaccination and ...
First, the phase 3 trial of Moderna’s norovirus vaccine had to endure a clinical hold. | First, the phase 3 trial of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback